Lipid A33-D268| ionizable lipid|DC Chemicals

Cas No.:
Chemical Name:	Lipid A33-D268
Synonyms:	Lipid A33 D268
SMILES:	CCCCCCCCC(CCCCCC)C(=O)OCCCN(CCCOC(=O)C(CCCCCC)CCCCCCCC)CC1=CNC(N)=N1
Formula:	C₄₂H₈₀O₄N₄
M.Wt:	705.13
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC60872	Lipid A33-D268	A33-D268 is an ionizable lipid derived from a 2-aminoimidazole (AM) core, featuring an asymmetric hydrophobic tail structure designed to optimize mRNA interactions. Selected as the top candidate from a 21-lipid library through molecular dynamics (MD) simulations, it demonstrated superior performance: low root mean square deviation (RMSD) and the smallest radius of gyration (Rg), indicating tight mRNA compaction, alongside moderate electrostatic energy and above-average hydrogen bonding for stable encapsulation. Formulated into LNPs, it achieves efficient muscle-specific transfection post-intramuscular injection, rivaling commercial ALC-0315 LNPs. Crucially, it exhibits 29-fold lower hepatic off-target expression, attributed to its inability to leverage serum protein coronas for liver tropism.
DC67530	HY-501	HY-501 is a next-generation cationically ionizable lipid engineered for high-efficiency RNA delivery developed by Biontech. Formulated at 40–50 mol% in lipid nanoparticles (LNPs) alongside DSPC, cholesterol, and polysarcosine-conjugated lipid C14pSar23, HY-501 yields uniform, stable particles (80–100 nm) with >90% RNA encapsulation. It demonstrates superior in vivo performance: driving 2-fold higher protein expression than benchmark lipids (EA-405/HY-405) in muscle tissue, minimizing off-target liver accumulation, and reducing immunogenic risks (near-zero complement activation and <5% hemolysis). Preclinically, HY-501-based LNPs encoding SARS-CoV-2 spike protein elicit potent neutralizing antibodies and T-cell responses, underscoring its utility in precision vaccines. Its combination of scalable synthesis, exceptional transfection efficiency, and biosafety establishes HY-501 as a transformative vector for therapeutic RNA delivery.